rs387907267
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000256.3(MYBPC3):c.2827C>T(p.Arg943Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.000013 in 1,612,276 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000012 ( 0 hom. )
Consequence
MYBPC3
NM_000256.3 stop_gained
NM_000256.3 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 6.30
Genes affected
MYBPC3 (HGNC:7551): (myosin binding protein C3) MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3 is expressed exclusively in heart muscle and is a key regulator of cardiac contraction. Mutations in this gene are a frequent cause of familial hypertrophic cardiomyopathy. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
?
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
?
Variant 11-47335120-G-A is Pathogenic according to our data. Variant chr11-47335120-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 37039.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-47335120-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.2827C>T | p.Arg943Ter | stop_gained | 27/35 | ENST00000545968.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.2827C>T | p.Arg943Ter | stop_gained | 27/35 | 5 | NM_000256.3 | P4 | |
MYBPC3 | ENST00000399249.6 | c.2827C>T | p.Arg943Ter | stop_gained | 26/34 | 5 | A2 |
Frequencies
GnomAD3 genomes ? AF: 0.0000263 AC: 4AN: 152170Hom.: 0 Cov.: 33
GnomAD3 genomes
?
AF:
AC:
4
AN:
152170
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000121 AC: 3AN: 247124Hom.: 0 AF XY: 0.0000223 AC XY: 3AN XY: 134306
GnomAD3 exomes
AF:
AC:
3
AN:
247124
Hom.:
AF XY:
AC XY:
3
AN XY:
134306
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000116 AC: 17AN: 1460106Hom.: 0 Cov.: 31 AF XY: 0.0000165 AC XY: 12AN XY: 726332
GnomAD4 exome
AF:
AC:
17
AN:
1460106
Hom.:
Cov.:
31
AF XY:
AC XY:
12
AN XY:
726332
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000263 AC: 4AN: 152170Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74338
GnomAD4 genome
?
AF:
AC:
4
AN:
152170
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74338
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
?
AF:
AC:
2
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:24
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Feb 01, 2021 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Pathogenic, no assertion criteria provided | provider interpretation | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Apr 27, 2017 | p.Arg943Stop in the MYBPC3 gene. In total the variant has been seen in at least 18 unrelated cases with weak segregation data. This variant was initially reported in Van Driest S et al. (2004) in one individual with HCM, in the presence of another missense variant (S166F) in the TNNI3 gene (note: p.S166F in TNNI3 is also currently considered a likely disease-causing variant). The authors noted that this patient, among the other 9 with multiple mutations identified, had significantly younger age of diagnosis, the most hypertrophy, and the highest incidence of myectomy and ICD placement when compared with single mutation carriers. This variant was absent from 200 control individuals screened in their study (100 African Americans and 100 European Americans). Michels et al. 2007 reports this p.Arg943Stop variant as a Dutch founder mutation, present in 15 of 100 Netherland families with HCM. Michels et al. 2009 subsequently reports this p.Arg943Stop variant in a study performing echocardiograms in genotyped HCM patients (8 of 27 with this particular variant), mutation carriers without LVH (7 of 27 family members), and 55 controls (this variant was present in 0 of 55 controls). Note, it is unclear whether these are overlapping with the 100 families reported in this group's 2007 study. Christiaans et al. 2010 also reports this variant as a founder mutation in the Netherlands. Tajsharghi et al. 2010 reports this variant seen in homozygous form in an infant with fatal cardiomyopathy and skeletal myopathy. The patient expressed the cardiac specific MyBPC isoform in skeletal muscle at transcript and protein levels. This was a similar finding in Deprez et al. 2005, where p.Arg943Stop was identified in a neonate with severe unexplained HCM who died within the first few weeks of life, in trans with a frameshift MYBPC3 variant. GeneDx reports that this variant has also been seen in multiple other unrelated individuals tested at GeneDx. This variant also segregates with disease in the patient's own family (as it is present in him, his father, and his aunt (all of whom have HCM)). This is a nonsense variant predicted to cause loss of normal protein function either through premature protein truncation or nonsense-mediated mRNA decay. Many other truncating or null variants have been identified in MYBPC3 in association with cardiomyopathy (ex. p.Trp792fs, p.Pro794fs, p.Lys1065fs, p.Cys1202fs, p.Pro1208fs, p.Trp1098ter, p.Glu1096ter, p.Cys1124ter, p.Gln1233ter). Furthermore, these types of variants in MYBPC3 are not seen in individuals without cardiomyopathy (Pan et al 2012). The variant was reported online in 3 of 122,257 individuals in the Genome Aggregation Consortium Dataset (gnomAD; http://gnomad.broadinstitute.org/), which currently includes variant calls on >140,000 unrelated individuals of African, Asian, European, Ashkenazi, Latino descent. Specifically, the variant was observed in 2 of 15,313 individuals of South Asian descent (MAF=0.006%) and 1 of 55,460 individuals of European descent. The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. Note that other variants with strong evidence for pathogenicity have been seen at similar frequencies in datasets like this so this does not necessarily rule out pathogenicity (Pan et al 2012). - |
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Sep 13, 2018 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 03, 2022 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Published functional studies using cardiomyocytes derived from induced pluripotent stem cells demonstrated this variant activates the nonsense-mediated decay pathway and results in aberrant calcium signaling and dysregulation of a set of other cardiac genes (Seeger et al., 2019); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 19666645, 23674513, 25335496, 26026863, 18761664, 22569109, 28214152, 30731207, 31006259, 31918855, 31513939, 30847666, 32480058, 22574137, 16679492, 25525159, 26936621, 15519027, 19858127, 27532257, 23396983, 24510615, 22857948, 24111713, 28794111, 28396031, 28005231, 23233322, 20624503, 21839045, 19356534, 19574547, 30165862, 28797094, 29447731, 30742251, 31323898, 33673806, 32665702, 33662488, 32746448, 20505798, 30586709) - |
Hypertrophic cardiomyopathy 4 Pathogenic:7
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Medical Genetics Ghent, University of Ghent | Jan 01, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | Sep 21, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Jun 02, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 2010 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.001%). Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000037039 / PMID: 14563344 / 3billion dataset). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | Oct 08, 2014 | - - |
Hypertrophic cardiomyopathy Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Royal Brompton Clinical Genetics And Genomics Laboratory, NHS South East Genomic Laboratory Hub | Oct 04, 2017 | This variant has been reported in mutiple unrelated HCM patients in the literature (refs 1-6, below), and has also been shown to segregate with disease in multiple affected individuals in several unrelated families (Wessels et al (2015) Eur J Hum Genet 23(7)922-928). Several other clinical laboraties have also detected the variant in HCM patients referred for genetic testing (ClinVar variation ID: 37039). The variant has also been detected in control populations at a very low frequency which is compatible with the prevalence of disease (ExAC and gnomAD databases). In view of the evidence, this variant is pathogenic. - References - 1. Alders et al. (2003) Eur Heart J. 24(20):1848-53. 2. Van et al. (2004) J Am Coll Cardiol. 44(9):1903-10. 3. Christiaans et al. (2010) Neth Heart J. 18(5):248-54. 4. Millat et al. (2010) Eur J Med Genet. 53(5):261-7. 5. Yiu et al. (2012) PLoS One. 7(5):e36115. 6. Alfares et al. (2015) Genet Med.17(11):880-8. - Population Controls alleles / total (frequency): Exome Aggregation Consortium (ExAC) - 2/117632 (0.00001700), RBH healthy cohort - 0/2144 (0.0) - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Human Genetics, University of Leuven | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 04, 2024 | This sequence change creates a premature translational stop signal (p.Arg943*) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is present in population databases (rs387907267, gnomAD 0.007%). This premature translational stop signal has been observed in individuals with hypertrophic cardiomyopathy (PMID: 19574547, 20505798, 20624503, 22574137, 22857948, 23233322, 24111713, 25335496). It is commonly reported in individuals of Dutch ancestry (PMID: 19574547, 20505798, 20624503, 22574137, 22857948, 23233322, 24111713, 25335496). ClinVar contains an entry for this variant (Variation ID: 37039). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 03, 2020 | The p.Arg943X variant in MYBPC3 has been reported in >25 individuals with hypertrophic cardiomyopathy (HCM) and segregated with disease in 4 affected relatives in 4 families (Alders 2003 PMID: 14563344, Lekanne Deprez 2006 PMID: 16679492, Foksteun 2008 PMID: 18409188, Morita 2008 PMID: 18403758, Michels 2009 PMID: 19356534, Van Driest 2004 PMID: 15519027, Tajsharghi 2010 PMID: 19858127, Yiu 2012 PMID: 22574137, Wessels 2014 PMID: 25335496, LMM unpublished data). Several of these individuals carried an additional clinically significant variant and presented with early onset disease. This variant has been reported by other clinical laboratories in ClinVar (Variation ID 37039) and has also been identified in 0.006% (2/30444) of South Asian chromosomes by gnomAD (https://gnomad.broadinstitute.org/). This nonsense variant leads to a premature termination codon at position 943, which is predicted to lead to a truncated or absent protein. Loss of function of the MYBPC3 gene is an established disease mechanism in autosomal dominant HCM. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM. ACMG/AMP criteria applied: PVS1, PS4, PP1, PM2_supporting. - |
Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 22, 2024 | This variant changes 1 nucleotide in exon 27 of the MYBPC3 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Functional RNA studies using cardiac tissue derived from a heterozygous carrier individual have shown that this variant causes a significant reduction in MYBPC3 mRNA levels (PMID: 33757590). This variant has been observed in over 20 unrelated individuals affected with hypertrophic cardiomyopathy (PMID: 16679492, 20624503, 22857948, 23233322, 24111713, 25335496, 27532257, 31006259, 31513939, 33757590, 36252119, 36835444) and is considered to be a founder mutation in the Dutch population (PMID: 20505798, 28794111). This variant has been reported to cause lethal cardiomyopathy or severe neonatal hypertrophic cardiomyopathy in individuals who were homozygous or compound heterozygous with another pathogenic mutation (PMID: 16679492, 24111713, 25335496, 30742251, 36178741). It has also been reported in two individuals affected with left ventricular noncompaction who both carried an additional different pathogenic variant (PMID: 31918855, 37963751), and in one individual affected with atrioventricular block (PMID: 35470684). This variant has been identified in 3/247124 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MYBPC3 function is a known mechanism of disease. Based on available evidence, this variant is classified as Pathogenic. - |
Cardiomyopathy Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 18, 2023 | This variant changes 1 nucleotide in exon 27 of the MYBPC3 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Functional RNA studies using cardiac tissue derived from a heterozygous carrier individual have shown that this variant causes a significant reduction in MYBPC3 mRNA levels (PMID: 33757590). This variant has been observed in over 20 unrelated individuals affected with hypertrophic cardiomyopathy (PMID: 16679492, 20624503, 22857948, 23233322, 24111713, 25335496, 27532257, 31006259, 31513939, 33757590, 36252119, 36835444) and is considered to be a founder mutation in the Dutch population (PMID: 20505798, 28794111). This variant has been reported to cause lethal cardiomyopathy or severe neonatal hypertrophic cardiomyopathy in individuals who were homozygous or compound heterozygous with another pathogenic mutation (PMID: 16679492, 24111713, 25335496, 30742251, 36178741). It has also been reported in two individuals affected with left ventricular noncompaction who both carried an additional different pathogenic variant (PMID: 31918855, 37963751), and in one individual affected with atrioventricular block (PMID: 35470684). This variant has been identified in 3/247124 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MYBPC3 function is a known mechanism of disease. Based on available evidence, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | May 28, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 20, 2023 | Variant summary: MYBPC3 c.2827C>T (p.Arg943X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 1.2e-05 in 247124 control chromosomes (gnomAD). c.2827C>T has been reported in the literature in multiple individuals affected with Hypertrophic Cardiomyopathy (e.g. Van Driest_2004, Deprez_2006, Michels_2007, Berge_2013). These data indicate that the variant is very likely to be associated with disease. 15 clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 24, 2021 | The p.R943* pathogenic mutation (also known as c.2827C>T) located in coding exon 27 of the MYBPC3 gene, results from a C to T substitution at nucleotide position 2827. This changes the amino acid from an arginine to a stop codon within coding exon 27. This mutation has been reported in multiple unrelated probands with hypertrophic cardiomyopathy, having been reported as a Dutch founder mutation (Van Driest SL et al. J Am Coll Cardiol. 2004; 44(9):1903-10; Michels M et al. Neth Heart J. 2007;15(5):184-90; Michels M et al. JACC Cardiovasc Imaging. 2009;2(1):58-64; Christiaans I et al. Neth Heart J. 2010;18(5):248-54; Brito D et al. Rev Port Cardiol. 2012;31(9):577-87; Hathaway J et al. BMC Cardiovasc Disord, 2021 03;21:126). This mutation has been reported as occurring in the homozygous state and also with other alterations in patients with severe, early onset disease with and without other findings such as skeletal myopathy, non-compaction and congenital heart defects (Lekanne Deprez RH et al. J Med Genet. 2006;43(10):829-32; Tajsharghi H et al. J Med Genet. 2010;47(8):575-7; Berge KE et al. Clin Genet. 2014;86(4):355-60; Wessels MW et al. Eur J Hum Genet. 2015;23(7):922-8; van Velzen HG et al. Circ Cardiovasc Genet, 2017 Aug;10:[Epub ahead of print]). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
A;A;A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at